Clinical trials: TPF
Head and Neck Squamous Cell Carcinoma
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
This study is a prospective, open-label, single-arm study. The trial will be divided into 3 phases: screening/baseline, treatment and follow-up.
- Trial name
- NCT05351762
- Testing
- Nimotuzumab Combined With Neoadjuvant Chemotherapy
- Volunteers
- 55 people
- Sponsor
- Xijing Hospital
Head and Neck Squamous Cell Carcinoma
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
This study compare the survival without laryngeal dysfunction 2 years after the end of treatment, obtained by chemotherapy followed by radiotherapy or chemotherapy with cisplatin administrated during radiotherapy.
- Trial name
- SALTORL (NCT03340896)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- France
- Volunteers
- 256 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
To Assess the Feasibility of CT-derived FFR, WSS and TPF on Coronary Atherosclerotic Plaque
Evaluation of FFR, WSS, and TPF Using CCTA
To assess the feasibility of CT-derived computed fractional flow reserve (FFRCT), wall shear stress and total plaque force on coronary atherosclerotic plaque and to collect the preliminary data to apply those parameters for the…
- Trial name
- NCT01857687
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Advanced Nasopharyngeal Carcinoma
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and…
- Trial name
- NCT03723343
- Testing
- GP+IMRT, TPF+IMRT
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Guiyang Medical University
Chemoradiation, Nasopharyngeal Carcinoma
Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb) will receive either cisplatin plus 5-fluorouracil (PF) or docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy with concurrent…
- Trial name
- ESNCCT (NCT01536223)
- Testing
- PF (cisplatin and 5-fluorouracil) group, TPF (docetaxel plus cisplatin and 5-fluorouracil) group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in untreated patients…
- Trial name
- NCT00209690
- Testing
- Taxotere, 5-FU, Briplatin
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
ESCC
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC
- Trial name
- NCT05050760
- Testing
- Camrelizumab, DCF
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Xijing Hospital
Mouth Neoplasms, Carcinoma, Squamous Cell
GDF15 Based TPF Induction Chemotherapy for OSCC Patients
The purpose of this study is to confirm the predictive value of GDF15 expression for TPF induction in T3/T4cN0M0 patients with OSCC
- Trial name
- NCT02285530
- Testing
- TPF induction chemotherapy, surgery group, Post-operative radiotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer of Larynx
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
The purpose of this study is to learn how to identify early which patients will respond to chemotherapy plus radiation therapy in order to reduce the number of subjects who require surgery (followed by radiation therapy).
- Trial name
- NCT00599131
- Testing
- Cisplatin, Cetuximab, 5-Fluorouracil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352118
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
This trial studies the efficacy and safty of paclitaxel in combination with cisplatin and 5-fluorouracil(TPF) induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma.
- Trial name
- NCT02976909
- Testing
- Paclitaxel+Cisplatin+5fluorouracil
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Yuhong Li
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
Tibial Plateau Fracture
TPF Machine Learning Algorithms
To adopt a machine learning technique to decide whether operative or non-operative treatment will result in the best patient-outcome.
- Trial name
- NCT04983316
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Nasopharyngeal Cancers
Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers
This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy to concurrent chemoradiotherapy alone, in…
- Trial name
- NPC2006 (NCT00828386)
- Testing
- Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
- Where
- 5 sites in France, Morocco and 2 more
- Volunteers
- 83 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Laryngeal Neoplasms
Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab
To evaluate the progression free time in patients with completed or partial response > 30% evaluated over primary tumour (damage T and N) after induction TPF (Docetaxel, Cisplatin, 5-FU) treated with RT + Cetuximab over 2 years.
- Trial name
- NCT00941135
- Testing
- Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Fundacion Miguel Servet
Head and Neck Cancer
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00646659
- Testing
- cetuximab, carboplatin, cisplatin
- Where
- Belgium
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mouth Neoplasms, Carcinoma, Squamous Cell
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC
- Trial name
- NCT02290145
- Testing
- TPF group, surgery group, Post-operative radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Medical Nutrition Therapy, Gestational Diabetes Mellitus
Medical Nutrition Therapy Combined With TPF-DM in Pregnant Women With Gestational Diabetes Mellitus
Background: Gestational diabetes mellitus (GDM), GDM is the first time of gestational impaired glucose tolerance in pregnant women. It is the most common complication disease in women of childbearing age.
- Conditions
- Medical Nutrition Therapy, Gestational Diabetes Mellitus, Adverse Pregnancy Outcomes, Fasting Plasma Glucose
- Trial name
- NCT03957603
- Testing
- Enteral Nutrition Suspension (TFP-DM), Medical Nutrition Therpay
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Medical University
Hypopharyngeal Cancer
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
The investigators will examine whether 2-cycles of DFP chemotherapy before definitive concurrent chemoradiation therapy (CCRT) can improve progression-free survival in locally advanced (Stage III \& IVM0) hypopharyngeal and base…
- Trial name
- NCT01312350
- Testing
- neoadjuvant docetaxel/cisplatin/fluorouracil, No treatment before definitive CCRT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center